Images

Several Alzheimer’s Disease therapies under investigation target Aβ or its aggregates and can generally be divided into four therapeutic aims: 1) reduce Aβ generation; 2) enhance degradation and clearance of Aβ; 3) neutralize soluble Aβ monomers or the resulting toxicity; 4) directly inhibit Aβ aggregation.

The table summarizes the high-level clinical characteristics of the existing and newly emerging pharmacological treatments for schizophrenia with at least one positive placebo-controlled trial.

LDT=Laterodorsal tegmental nucleus; NAc = Nucleus Accumbens; SN = Substantia Nigra; VTA = Ventral Tegmental Area.

Stimulation of M1 receptors in layer II/III of the frontal cortex, however, increases acetylcholine, which in turn stimulates the inhibitory GABAergic interneuron.

An overview of percentage change in selected cause of death (for all ages) from 2000-2019. The image shows, that Alzheimer’s disease, by far, has the biggest percentage change (145.2%) as a cause of death.

By 2025, it is predicted that the number of individuals aged ≥65 years with AD dementia in the US will reach 7.2 million, which is a 7% increase from 6.7 million affected individuals in 2023.